Acute Myeloid Leukemia (non-APL) · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | supportive_care |
| Linked regimen | None |
| ID | IND-EMERG-TLS-PROPHYLAXIS-RASBURICASE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-NCCN-AML-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Emergency supportive-care indication for TLS prophylaxis in high-risk hematologic malignancies. time_critical=true: must initiate before / concurrent with cytotoxic therapy. Cross-disease relevance (AML, Burkitt, B-ALL, bulky lymphoma) — disease_id=DIS-AML used as proxy; engine should fire across multiple disease pathways. Reference SUP-TLS-PROPHYLAXIS exists for intermediate-risk allopurinol-only protocol.
Used By
Algorithms
ALGO-AML-1L- ALGO-AML-1L